PTC Therapeutics (PTCT) Misses Q4 EPS by 78c; Offers FY23 Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. TSLA
6. META
7. RTX
8. SMCI
9. GOOGL
10. S

Go back to PTC Therapeutics (PTCT) Misses Q4 EPS by 78c; Offers FY23 Guidance

PTC Therapeutics Provides a Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

February 21, 2023 4:05 PM EST

2022 total revenue of $699 million, representing 30% year-over-year growth, or $740 million and 37% growth at CER*

Guidance for full-year 2023 total revenue of $940 million to $1 billion reaffirmed

Four important study readouts expected in first half of 2023, three of them registration-directed

SOUTH PLAINFIELD, N.J., Feb. 21, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and financial results for the fourth quarter and full year ending December 31, 2022.  

"2023 will... More